Patent application number | Description | Published |
20080219998 | Anti-Thrombotic Agents - The present invention embodies: methods; compounds, their pharmaceutically acceptable analogs, isomer, salts, hydrates, solvates and prodrug derivatives, and pharmaceutically acceptable compositions thereof that have particular biological properties; devices; diagnostic and other assays; and the uses of such methods, compounds, devices and assays. Common throughout these embodiments is specific selective reduction of intravascular thromboplastin antecedent activity, which results in a safe antithrombotic effect. A particularly prominent application or the invention relates to diagnosis and treatment of patients which have, or are at risk of, developing thrombosis, thrombotic injury, or vaso-occlusive diseases, such as myocardial infarction, stroke, restenosis after angioplasty, thrombotic diseases, etc. Another particularly prominent feature of the present invention is its high level of hemostatic safety at optimal efficacy. Also, the present invention is compatible for use in combination with other traditional therapeutic agent such as another antithrombotic, antiplatelet, thrombolytic, or anticoagulant agents. | 09-11-2008 |
20100158890 | USE OF THROMBIN MUTANTS TO INHIBIT THE ANTICOAGULATION EFFECT OF THROMBIN INHIBITORS - The present invention provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present invention include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent, particularly hemostatic agents such as activated factor VII or activated prothrombin complex concentrate. In one embodiment of the invention, the methods are useful in the treatment of patients in which a direct thrombin inhibitor has been administered, particularly argatroban. The present invention further provides a method for quantifying the concentration of an anticoagulant in the plasma or whole blood of a patient using a variant prothrombin or thrombin titration assay. | 06-24-2010 |
20100184672 | PROTEIN C FOR USE IN MAINTAINING HEMOSTASIS - It is disclosed herein that protein C functions as a hemostatic agent. Thus, provided is a method of preventing, treating or ameliorating abnormal bleeding in a subject, comprising administering to the subject a protein C polypeptide or polynucleotide. Abnormal bleeding can result from a bleeding disorder, such as hemophilia or a platelet disorder, or from a bleeding episode, such as from a traumatic injury. | 07-22-2010 |
20110020349 | ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. Methods for making an anti-factor XI monoclonal antibody, or epitope-binding fragments, variants, or derivatives thereof, are also provided. | 01-27-2011 |
20110250207 | ANTI-FXI ANTIBODIES AND METHODS OF USE - Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use. | 10-13-2011 |
20120164129 | EXPRESSION OF THROMBIN VARIANTS - One aspect of the invention contemplates a mutant E-WE thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence. Another aspect contemplates a thrombin precursor that contains the amino acid residue sequence Asp/Glu-Gly-Arg at positions 325, 326 and 327 based on the preprothrombin sequence. A third aspect contemplates a thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence as well as the amino acid residue sequence Asp/Glu Gly Arg at positions 325, 326 and 327 based on the preprothrombin sequence. Also contemplated is a composition that contains an effective amount of mutant thrombin dissolved or dispersed in a pharmaceutically acceptable carrier. A method is also disclosed for enhancing treating and preventing thrombosis in a mammal in need using that composition. | 06-28-2012 |
20120276112 | ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. | 11-01-2012 |
20130064807 | USE OF THROMBIN MUTANTS TO INHIBIT THE ANTICOAGULATION EFFECT OF THROMBIN INHIBITORS - The present disclosure provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present disclosure include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent. In one embodiment, the methods are useful in the treatment of patients in which a direct thrombin inhibitor has been administered. The present disclosure further provides a method for quantifying the concentration of an anticoagulant in the plasma or whole blood of a patient using a variant prothrombin or thrombin titration assay. | 03-14-2013 |
20130129745 | ANTI-FXI ANTIBODIES AND METHODS OF USE - Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use. | 05-23-2013 |
20130171144 | ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. | 07-04-2013 |
20140322219 | ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. | 10-30-2014 |
20150093395 | ANTI-FXI ANTIBODIES AND METHODS OF USE - Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use. | 04-02-2015 |
20150315292 | ANTIBODIES AGAINST FACTOR XII AND USES THEREOF - Provided are antibodies that selectively bind to and inhibit activation of coagulation factor XII. Methods of treatment employing these antibodies are described herein. | 11-05-2015 |
20150322163 | ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF - Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the disclosure include administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. | 11-12-2015 |
Patent application number | Description | Published |
20080227107 | COMPOSITIONS AND METHODS FOR LABELING OF NUCLEIC ACID MOLECULES - The present invention is generally related to compositions, kits and methods for labeling nucleic acid molecules using reverse transcriptases, preferably multi-subunit reverse transcriptases such as ASLV reverse transcriptases. Specifically, the invention relates to methods, kits and compositions for fluorescently labeling nucleic acid molecules during nucleic acid synthesis. The labeled nucleic acid molecules produced in accordance with the invention are particularly suited as labeled probes for nucleic acid detection and diagnostics. | 09-18-2008 |
20080287321 | cDNA synthesis improvements - The present invention generally relates to methods of making cDNA molecules and cDNA libraries. The invention also relates to cDNA molecules and cDNA libraries produced according to these methods, as well as to vectors and host cells containing such cDNA molecules and libraries. The invention also relates to kits for making the cDNA molecules and libraries of the invention. | 11-20-2008 |
20090176242 | COMPOSITIONS AND METHODS FOR LABELING OF NUCLEIC ACID MOLECULES - The present invention is generally related to compositions, kits and methods for labeling nucleic acid molecules using reverse transcriptases, preferably multi-subunit reverse transcriptases such as ASLV reverse transcriptases. Specifically, the invention relates to methods, kits and compositions for fluorescently labeling nucleic acid molecules during nucleic acid synthesis. The labeled nucleic acid molecules produced in accordance with the invention are particularly suited as labeled probes for nucleic acid detection and diagnostics. | 07-09-2009 |
20100093989 | Methods For Production And Purification Of Nucleic Acid Molecules - The present invention is directed to methods for the production and isolation of nucleic acid molecules. In particular, the invention concerns isolation of mRNA molecules and the production and isolation of nucleic acid molecules (e.g., cDNA molecules or libraries), which may be single- or double-stranded. Additionally, the invention concerns selection and isolation of particular nucleic acid molecules of interest from a sample which may contain a population of molecules. Specifically, the invention concerns affinity-labeled primer-adapter molecules which allow improved isolation and production of such nucleic acid molecules, increasing both product recovery and speed of isolation. | 04-15-2010 |
20100168408 | COMPOSITIONS AND METHODS FOR LABELING OF NUCLEIC ACID MOLECULES - The present invention is generally related to compositions, kits and methods for labeling nucleic acid molecules using reverse transcriptases, preferably multi-subunit reverse transcriptases such as ASLV reverse transcriptases. Specifically, the invention relates to methods, kits and compositions for to fluorescently labeling nucleic acid molecules during nucleic acid synthesis. The labeled nucleic acid molecules produced in accordance with the invention are particularly suited as labeled probes for nucleic acid detection and diagnostics. | 07-01-2010 |
20100317063 | COMPOSITIONS FOR IMPROVED cDNA SYNTHESIS - The present invention generally relates to methods of making cDNA molecules and cDNA libraries. The invention also relates to cDNA molecules and cDNA libraries produced according to these methods, as well as to vectors and host cells containing such cDNA molecules and libraries. The invention also relates to kits for making the cDNA molecules and libraries of the invention. | 12-16-2010 |
20110151521 | cDNA SYNTHESIS IMPROVEMENTS - The present invention generally relates to methods of making cDNA molecules and cDNA libraries. The invention also relates to cDNA molecules and cDNA libraries produced according to these methods, as well as to vectors and host cells containing such cDNA molecules and libraries. The invention also relates to kits for making the cDNA molecules and libraries of the invention. | 06-23-2011 |
20120107879 | METHODS FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID MOLECULES - The present invention is directed to methods for the production and isolation of nucleic acid molecules. In particular, the invention concerns isolation of mRNA molecules and the production and isolation of nucleic acid molecules (e.g., cDNA molecules or libraries), which may be single- or double-stranded. Additionally, the invention concerns selection and isolation of particular nucleic acid molecules of interest from a sample which may contain a population of molecules. Specifically, the invention concerns affinity-labeled primer-adapter molecules which allow improved isolation and production of such nucleic acid molecules, increasing both product recovery and speed of isolation. | 05-03-2012 |
Patent application number | Description | Published |
20130065275 | SERUM-FREE MAMMALIAN CELL CULTURE MEDIUM, AND USES THEREOF - The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells. | 03-14-2013 |
20130295667 | SERUM-FREE MAMMALIAN CELL CULTURE MEDIUM, AND USES THEREOF - The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells. | 11-07-2013 |
20140057335 | CULTURE MEDIUM FOR CELL GROWTH AND TRANSFECTION - The present invention is directed generally to cell culture media useful for introducing macromolecules and compounds (e.g., nucleic acid molecules) into cells (e.g., eukaryotic cells in the presence of said media. Cells containing introduced materials can be further cultured in the media. In particular, the invention allows introduction of nucleic acid molecules (e.g., vectors) into cells (particularly eukaryotic cells) and expression of proteins encoded by the nucleic acid molecules in the cells. The invention obviates the need to change the cell culture medium each time a different procedure is performed with the cells (e.g., culturing cells vs. transfecting cells). The invention thus provides efficient and high throughput methods to transform/transfect culture and cells avoiding the need for multiple manipulations and transfers of cells during transfection and expression studies. | 02-27-2014 |
20150079659 | SERUM-FREE MAMMALIAN CELL CULTURE MEDIUM, AND USES THEREOF - The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells. | 03-19-2015 |
Patent application number | Description | Published |
20100143451 | Composition for Improving Skin Condition and Appearance - Disclosed is a cosmetic composition comprising prenylated isoflavonoid and a carrier, wherein the prenylated isoflavonoid is from about 0.0000001% to about 10%, preferably from 0.00001% to 1%, most preferably from 0.01% to 1%, by weight, based on the total weight of the composition. The active agent prenylated isoflavonoid induces a statistically significant upregulation of collagen 1A1 and elastin genes in normal human dermal fibroblasts. The composition is effective to stimulate the production of collagen and elastin and improve the appearance and condition of the skin. | 06-10-2010 |
20110091406 | COMPOSITION AND METHOD FOR PROTECTING LABILE ACTIVE COMPONENTS DURING HIGH TEMPERATURE DRYING - A composition and method for protecting personal care components, advantageously labile active personal care components, from decomposition during high temperature drying, employing water-soluble hydrolyzed polysaccharide encapsulants. Also disclosed is an additive for a personal care composition comprising a personal care component that is at least partially encapsulated within a hydrolyzed polysaccharide encapsulant. Also disclosed is a method for protecting a composition containing labile biologically active particles which comprises encapsulating at least a portion of the biologically active particles within hydrolyzed polysaccharide particles, thereby protecting said portion of said biologically active particles. | 04-21-2011 |
20130164234 | COMPOSITION FOR TREATING SKIN PIGMENTATION - The invention relates to a topical composition containing a bilirubin-producing plant extract. In particular, the bilirubin-producing plant extract is obtained from the genus | 06-27-2013 |
20150190337 | COMPOSITION FOR TREATING SKIN PIGMENTATION - The invention relates to a topical composition containing a bilirubin-producing plant extract. In particular, the bilirubin-producing plant extract is obtained from the genus | 07-09-2015 |
20150328115 | ANTIMICROBIAL BISPYRIDINE AMINE COMPOSITIONS AND USES - Antimicrobial bispyridine amine compositions that facilitate easy application on the skin, do not penetrate the skin, are compatible with typical deodorant ingredients, and do not cause adverse effects on skin and clothing. In one aspect, the present invention relates to an antimicrobial composition including an organic acid salt of a bispyridine amine where the organic acid contains from about 4 to about 30 carbon atoms. Because the organic acid salts of bispyridine amines are large molecules, they will not easily penetrate the skin, and will stay on the surface where they were applied and where they are needed to have their effect. | 11-19-2015 |
Patent application number | Description | Published |
20100021532 | Personal care composition containing yeast/polyphenol ferment extract - Disclosed is a yeast/polyphenol ferment extract, and a personal care composition including the yeast/polyphenol ferment extract. Also disclosed is a method for preparing and using the yeast/polyphenol extract and the personal care composition. | 01-28-2010 |
20110052676 | Composition For Delaying Cellular Senescence - Disclosed herein is a composition for delaying cellular senescence comprising from about 0.01 wt % to about 5 wt % of Hexapeptide-11(Phe-Val-Ala-Pro-Phe-Pro), based on the total weight of the composition, and a dermatologically-acceptable carrier for the peptide selected from the group consisting of water, oil, alcohol, silicone, and combinations thereof. | 03-03-2011 |
20120121522 | METABOLIZED CONDITIONED GROWTH MEDIUM AND METHODS OF USE - Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition. | 05-17-2012 |
20120128755 | Personal Care Composition Containing Yeast Extract And Hexapeptide - A personal care composition comprising (a) a yeast extract, (b) Hexapeptide-11 (Phe-Val-Ala-Pro-Phe-Pro) (SEQ ID NO:1), and (c) a determatologically-acceptable carrier, wherein the total amount of components (a) and (b) is from about 2 wt % to about 6 wt %, preferably from 4-6% based on the total weight of the personal care composition. Also disclosed is a method for regulating skin conditions by using this composition. | 05-24-2012 |
20120263807 | Topical compositions and methods for influencing electromagnetic radiation on cutaneous extracellular matrix protein production - Disclosed herein is a composition that is suitable for influencing electromagnetic radiation on cutaneous extracellular matrix protein production. The composition contains (a) a proanthrocyanin, a polyphenol or a proanthrocyanin/polyphenol-containing plant extract, absorbed or adsorbed onto an inert carrier, where component (a) is responsive to UV, IR or visible light; (b) a photo-activatable amino acid or amino acids blend; and (c) a dermatologically-acceptable vehicle, wherein component (a) is present in an amount of from about 15 wt % to about 35 wt % based on the total amount of component (a) and component (b), said component (b) is present in an amount of from about 65 wt % to about 85 wt % based on the total amount of component (a) and component (b), and said component (c) is present in an amount of from about 90 wt % to about 99.95 wt % based on the total weight of the composition. | 10-18-2012 |
20120301411 | MODULATING EPIGENETIC DNA METHYLATION TO CAUSE CELLS TO ADOPT DNA METHYLATION PATTERNS ASSOCIATED WITH YOUNG CELLS - Disclosed herein is a topical composition that contains (a) a plant meristem conditioned nutrient medium derived from the plants of the genus | 11-29-2012 |
20130101576 | COMPOSITION CONTAINING AN EXTRACT OF A SEQUENTIAL OR SIMULTANEOUS FERMENTATION - Disclosed herein is a topical composition that contains a fermentation extract from a simultaneous or sequential fermentation. When topically applied to skin, the composition of the invention is effective in stimulating the production of hyaluronic acid, CD44 and Caspase 14 protein in skin cells. | 04-25-2013 |
20140037675 | PROCESS FOR PREPARING METABOLIZED CONDITIONED GROWTH MEDIA - Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition. | 02-06-2014 |
20140037676 | PROCESS FOR PREPARING METABOLIZED CONDITIONED GROWTH MEDIA - Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition. | 02-06-2014 |
20140037677 | PROCESS FOR PREPARING METABOLIZED CONDITIONED GROWTH MEDIA - Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition. | 02-06-2014 |
20140038256 | PROCESS FOR PREPARING METABOLIZED CONDITIONED GROWTH MEDIA - Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition. | 02-06-2014 |
20140045240 | PROCESS FOR PREPARING METABOLIZED CONDITIONED GROWTH MEDIA - Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition. | 02-13-2014 |
20140178315 | Topical Compositions Comprising Ionic Fluids - The present invention relates to anhydrous or essentially anhydrous compositions intended for topical application on keratinaceous surfaces, wherein the composition includes a) an ionic fluid and b) a thickener. The compositions are advantageous for allowing the ionic fluid to act as the continuous phase of a topical formulation. | 06-26-2014 |
Patent application number | Description | Published |
20100181239 | Integrated High Throughput System for the Analysis of Biomolecules - Described is an affinity microcolumn comprising a high surface area material, which has high flow properties and a low dead volume, contained within a housing and having affinity reagents bound to the surface of the high surface area material that are either activated or activatable. The affinity reagents bound to the surface of the affinity microcolumn further comprise affinity receptors for the integration into high throughput analysis of biomolecules. | 07-22-2010 |
20110192778 | INTEGRATED HIGH THROUGHPUT SYSTEM FOR THE ANALYSIS OF BIOMOLECULES - Described is an affinity microcolumn comprising a high surface area material, which has high flow properties and a low dead volume, contained within a housing and having affinity reagents bound to the surface of the high surface area material that are either activated or activatable. The affinity reagents bound to the surface of the affinity microcolumn further comprise affinity receptors for the integration into high throughput analysis of biomolecules. | 08-11-2011 |
20120085692 | INTEGRATED HIGH THROUGHPUT SYSTEM FOR THE ANALYSIS OF BIOMOLECULES - Described is an affinity microcolumn comprising a high surface area material, which has high flow properties and a low dead volume, contained within a housing and having affinity reagents bound to the surface of the high surface area material that are either activated or activatable. The affinity reagents bound to the surface of the affinity microcolumn further comprise affinity receptors for the integration into high throughput analysis of biomolecules. | 04-12-2012 |
20130153479 | INTEGRATED HIGH THROUGHPUT SYSTEM FOR THE ANALYSIS OF BIOMOLECULES - Described is an affinity microcolumn comprising a high surface area material, which has high flow properties and a low dead volume, contained within a housing and having affinity reagents bound to the surface of the high surface area material that are either activated or activatable. The affinity reagents bound to the surface of the affinity microcolumn further comprise affinity receptors for the integration into high throughput analysis of biomolecules. | 06-20-2013 |
20140193311 | INTEGRATED HIGH THROUGHPUT SYSTEM FOR THE ANALYSIS OF BIOMOLECULES - Described is an affinity microcolumn comprising a high surface area material, which has high flow properties and a low dead volume, contained within a housing and having affinity reagents bound to the surface of the high surface area material that are either activated or activatable. The affinity reagents bound to the surface of the affinity microcolumn further comprise affinity receptors for the integration into high throughput analysis of biomolecules. | 07-10-2014 |
20160003841 | INTEGRATED HIGH THROUGHPUT SYSTEM FOR THE ANALYSIS OF BIOMOLECULES - Described is an affinity microcolumn comprising a high surface area material, which has high flow properties and a low dead volume, contained within a housing and having affinity reagents bound to the surface of the high surface area material that are either activated or activatable. The affinity reagents bound to the surface of the affinity microcolumn further comprise affinity receptors for the integration into high throughput analysis of biomolecules. | 01-07-2016 |
Patent application number | Description | Published |
20090171129 | RECOVERY OF HIGHER ALCOHOLS FROM DILUTE AQUEOUS SOLUTIONS - This invention is directed to methods for recovery of C3-C6 alcohols from dilute aqueous solutions, such as fermentation broths. Such methods provide improved volumetric productivity for the fermentation and allows recovery of the alcohol. Such methods also allow for reduced energy use in the production and drying of spent fermentation broth due to increased effective concentration of the alcohol product by the simultaneous fermentation and recovery process which increases the quantity of alcohol produced and recovered per quantity of fermentation broth dried. Thus, the invention allows for production and recovery of C3-C6 alcohols at low capital and reduced operating costs. | 07-02-2009 |
20090215137 | METHODS FOR THE ECONOMICAL PRODUCTION OF BIOFUEL PRECURSOR THAT IS ALSO A BIOFUEL FROM BIOMASS - Methods for producing a biofuel precursor are provided. Also provided are biocatalysts that convert a feedstock to a biofuel precursor. | 08-27-2009 |
20090246842 | ENGINEERED MICROORGANISMS FOR PRODUCING PROPANOL - Methods and compositions for the production of bio-based material precursors are provided. | 10-01-2009 |
20090299109 | Renewable Compositions - The present invention is directed to renewable compositions derived from fermentation of biomass, and integrated methods of preparing such compositions. | 12-03-2009 |
20120040080 | METHODS FOR THE ECONOMICAL PRODUCTION OF BIOFUEL PRECURSOR THAT IS ALSO A BIOFUEL FROM BIOMASS - Methods for producing a biofuel precursor are provided. Also provided are biocatalysts that convert a feedstock to a biofuel precursor. | 02-16-2012 |
20120064590 | RECOVERY OF HIGHER ALCOHOLS FROM DILUTE AQUEOUS SOLUTIONS - This invention is directed to methods for recovery of C3-C6 alcohols from dilute aqueous solutions, such as fermentation broths. Such methods provide improved volumetric productivity for the fermentation and allows recovery of the alcohol. Such methods also allow for reduced energy use in the production and drying of spent fermentation broth due to increased effective concentration of the alcohol product by the simultaneous fermentation and recovery process which increases the quantity of alcohol produced and recovered per quantity of fermentation broth dried. Thus, the invention allows for production and recovery of C3-C6 alcohols at low capital and reduced operating costs. | 03-15-2012 |
20120107890 | RECOVERY OF HIGHER ALCOHOLS FROM DILUTE AQUEOUS SOLUTIONS - This invention is directed to methods for recovery of C3-C6 alcohols from dilute aqueous solutions, such as fermentation broths. Such methods provide improved volumetric productivity for the fermentation and allows recovery of the alcohol. Such methods also allow for reduced energy use in the production and drying of spent fermentation broth due to increased effective concentration of the alcohol product by the simultaneous fermentation and recovery process which increases the quantity of alcohol produced and recovered per quantity of fermentation broth dried. Thus, the invention allows for production and recovery of C3-C6 alcohols at low capital and reduced operating costs. | 05-03-2012 |
20120107891 | RECOVERY OF HIGHER ALCOHOLS FROM DILUTE AQUEOUS SOLUTIONS - This invention is directed to methods for recovery of C3-C6 alcohols from dilute aqueous solutions, such as fermentation broths. Such methods provide improved volumetric productivity for the fermentation and allows recovery of the alcohol. Such methods also allow for reduced energy use in the production and drying of spent fermentation broth due to increased effective concentration of the alcohol product by the simultaneous fermentation and recovery process which increases the quantity of alcohol produced and recovered per quantity of fermentation broth dried. Thus, the invention allows for production and recovery of C3-C6 alcohols at low capital and reduced operating costs. | 05-03-2012 |
20120238787 | RENEWABLE COMPOSITIONS - The present invention is directed to renewable compositions derived from fermentation of biomass, and integrated methods of preparing such compositions. | 09-20-2012 |
20120259146 | RENEWABLE COMPOSITIONS - The present invention is directed to renewable compositions derived from fermentation of biomass, and integrated methods of preparing such compositions. | 10-11-2012 |
20120323055 | RENEWABLE COMPOSITIONS - The present invention is directed to renewable compositions derived from fermentation of biomass, and integrated methods of preparing such compositions. | 12-20-2012 |
20130059370 | RECOVERY OF HIGHER ALCOHOLS FROM DILUTE AQUEOUS SOLUTIONS - This invention is directed to methods for recovery of C3-C6 alcohols from dilute aqueous solutions, such as fermentation broths. Such methods provide improved volumetric productivity for the fermentation and allows recovery of the alcohol. Such methods also allow for reduced energy use in the production and drying of spent fermentation broth due to increased effective concentration of the alcohol product by the simultaneous fermentation and recovery process which increases the quantity of alcohol produced and recovered per quantity of fermentation broth dried. Thus, the invention allows for production and recovery of C3-C6 alcohols at low capital and reduced operating costs. | 03-07-2013 |
20130183730 | RECOVERY OF HIGHER ALCOHOLS FROM DILUTE AQUEOUS SOLUTIONS - This invention is directed to methods for recovery of C3-C6 alcohols from dilute aqueous solutions, such as fermentation broths. Such methods provide improved volumetric productivity for the fermentation and allows recovery of the alcohol. Such methods also allow for reduced energy use in the production and drying of spent fermentation broth due to increased effective concentration of the alcohol product by the simultaneous fermentation and recovery process which increases the quantity of alcohol produced and recovered per quantity of fermentation broth dried. Thus, the invention allows for production and recovery of C3-C6 alcohols at low capital and reduced operating costs. | 07-18-2013 |
20130261323 | INTEGRATED METHODS OF PREPARING RENEWABLE CHEMICALS - Isobutene, isoprene, and butadiene are obtained from mixtures of C | 10-03-2013 |
20130273622 | Methods for the Economical Production of Biofuel from Biomass - Methods for producing a biofuel are provided. Also provided are biocatalysts that convert a feedstock to a biofuel. | 10-17-2013 |
20140163267 | RENEWABLE COMPOSITIONS - The present invention is directed to renewable compositions derived from fermentation of biomass, and integrated methods of preparing such compositions. | 06-12-2014 |
20140360376 | RECOVERY OF HIGHER ALCOHOLS FROM DILUTE AQUEOUS SOLUTIONS - This invention is directed to methods for recovery of C3-C6 alcohols from dilute aqueous solutions, such as fermentation broths. Such methods provide improved volumetric productivity for the fermentation and allows recovery of the alcohol. Such methods also allow for reduced energy use in the production and drying of spent fermentation broth due to increased effective concentration of the alcohol product by the simultaneous fermentation and recovery process which increases the quantity of alcohol produced and recovered per quantity of fermentation broth dried. Thus, the invention allows for production and recovery of C3-C6 alcohols at low capital and reduced operating costs. | 12-11-2014 |
20150126787 | RENEWABLE COMPOSITIONS - The present invention is directed to renewable compositions derived from fermentation of biomass, and integrated methods of preparing such compositions. | 05-07-2015 |
20150307904 | Methods for the Economical Production of Biofuel from Biomass - Methods for producing a biofuel are provided. Also provided are biocatalysts that convert a feedstock to a biofuel. | 10-29-2015 |